West Pharmaceutical
WST
777 hedge funds and large institutions have $22.4B invested in West Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 278 increasing their positions, 293 reducing their positions, and 77 closing their positions.
43% more call options, than puts
Call options by funds: $148M | Put options by funds: $104M
14% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 77
0.15% more ownership
Funds ownership: 93.62% → 93.77% (+0.15%)
0% less funds holding
Funds holding: 778 → 777 (-1)
5% less repeat investments, than reductions
Existing positions increased: 278 | Existing positions reduced: 293
17% less capital invested
Capital invested by funds: $27B → $22.4B (-$4.6B)
67% less funds holding in top 10
Funds holding in top 10: 9 → 3 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$566M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$150M |
| 3 |
LGF
LGT Group Foundation
Vaduz,
Liechtenstein
|
+$73.9M |
| 4 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
+$68.9M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$63.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$276M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$136M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$120M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$116M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$65.9M |
WST Hedge Fund Activity: Q2 2024 in Review
777 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2024, worth a combined $22.4B — down 17% from $27B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new WST positions and 77 closed out — a net gain of 11 holders — while 278 added to existing stakes and 293 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $566M. The largest seller was Citadel Advisors, cutting an estimated $276M.
- 777 institutional investors held West Pharmaceutical (WST) as of Q2 2024, down from 778 in Q1 2024.
- Funds reported $22.4B of West Pharmaceutical stock for Q2 2024, down 17% quarter-over-quarter.
- 88 funds opened new West Pharmaceutical positions in Q2 2024 and 77 closed out, a net change of +11 holders.
- The largest West Pharmaceutical buyer in Q2 2024 was AllianceBernstein, an estimated $566M added.
- The largest West Pharmaceutical seller in Q2 2024 was Citadel Advisors, an estimated $276M sold.
Based on aggregated 13F filings for Q2 2024.